Loading...
Uploaded by pharmapricing on Mar 24, 2011
This pharma pricing video compares Sutent and Nexavar sales, quarterly, over the last 4 years and analyses market access opportunities. Specifically, we focus on the implications of heptacellular carcinoma (HCC) approval in Nexavar.Learn more at http://pharmapricing.org/about-me-2
Science & Technology
Standard YouTube License
Load more suggestions
Link to this comment:
All Comments (0)